Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

  1. Vilsbøll, T.
  2. Blevins, T.C.
  3. Jodar, E.
  4. Poulter, N.
  5. Tentolouris, N.
  6. Ross Agner, B.F.
  7. Lehmann, L.
  8. Leiter, L.A.
Journal:
Diabetes, Obesity and Metabolism

ISSN: 1463-1326,  1462-8902

Year of publication: 2019

Volume: 21

Issue: 6

Pages: 1506-1512

Type: Article

DOI: 10.1111/DOM.13675 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus